Binu V. John

Binu V. John

Auto-generated profile, based on publicly available information

Binu V. John

Department of Medicine, University of Miami and Miami VA Health System, Miami, Florida, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
ASAmit Singal
Amit Singal
NRNicole E. Rich
Nicole E. Rich
NMNeil Mehta MD
Neil Mehta MD
ABAndrea D. Branch
Andrea D. Branch
APAnjana Pillai
Anjana Pillai
CMCaitlin C. Murphy
Caitlin C. Murphy

1 June 2023 in Hepatology Communications
Verified
Journal Article
Open access
JTJuan Trivella
Juan Trivella
BJBinu V. John
Binu V. John
CLCynthia Levy
Cynthia Levy
Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. The incidence and prevalence of PBC vary widely in different regions and time periods, and although disproportionally more common among White non-Hispanic females, contemporary data show a higher prevalence in males and racial minorities than previously described. Outcomes largely depend on early recognition of the disease and prompt institution of treatment, which, in turn, are directly influenced by provider bias and socioeconomic factors. Ursodeoxycholic acid remains the initial treatment of choice for PBC, with obeticholic acid and fibrates (off-label therapy) reserved as add-on therapy for the management of inadequate responders or those with ursodeoxycholic acid intolerance. Novel and repurposed drugs are currently at different stages of clinical development not only for the treatment of PBC but also for its symptomatic management. Here, we summarize the most up-to-date data regarding the epidemiology, prognosis, and treatment of PBC, providing clinically useful information for its holistic management.

1 May 2019 in Gastroenterology
Verified
Journal Article
Open access
DKDavid Edward Kaplan
David Edward Kaplan
MSMarina A. Serper
Marina A. Serper
RMRajni Mehta
Rajni Mehta
RFRena Fox
Rena Fox
BJBinu John
Binu John
TTTamar H. Taddei
Tamar H. Taddei
Concerns related to hepatotoxicity frequently lead to discontinuation or non-initiation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase therapy in patients with cirrhosis despite data supporting statin use. We investigated the independent effects of hyperlipidemia and statin exposure on mortality, hepatic decompensation, and hepatocellular carcinoma development in a large national cohort of patients with cirrhosis. We performed a retrospective cohort study of patients with newly diagnosed cirrhosis from January 1, 2008 through June 30, 2016 in the Veterans Health Administration. Subjects were divided into 2 cohorts: 21,921 patients with prior statin exposure (existing users) and 51,023 statin-naïve individuals, of whom 8794 subsequently initiated statin therapy (new initiators) and 44,269 did not (non-initiators). Multivariable Cox proportional hazard models with inverse probability weighting were constructed to assess the effects of time-updating lipid profiles and cumulative exposure to statins on survival and hepatic decompensation. Statin-naïve new initiators were propensity matched with non-initiators to simulate a randomized controlled trial of statin use in cirrhosis. In statin-naïve subjects, every 10-mg/dL increase in baseline total cholesterol was associated with a 3.6% decrease in mortality. In existing users, each year of continued statin exposure was associated with a hazard ratio of 0.920 (95% confidence interval 0.0.897-0.943) for mortality. After risk-set matching, each year of statin exposure among new initiators was associated with a hazard ratio of 0.913 (95% confidence interval 0.890-0.937) for mortality. In a retrospective cohort study of veterans with a new diagnosis of cirrhosis, we associated hypercholesterolemia with well-preserved hepatic function and decreased mortality. Nonetheless, each cumulative year of statin exposure was associated with an independent 8.0%-8.7% decrease of mortality of patients with cirrhosis of Child-Turcotte-Pugh classes A and B.

27 December 2019 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
BJBinu V. John
Binu V. John
ELEleanor Love
Eleanor Love
BDBassam Dahman
Bassam Dahman
NKNargiza Kurbanova
Nargiza Kurbanova
VKVenkata Rajesh Konjeti
Venkata Rajesh Konjeti
MSMohammad S. Siddiqui
Mohammad S. Siddiqui

1 October 2021 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
BJBinu V. John
Binu V. John
YDYangyang Deng
Yangyang Deng
ASAndrew Scheinberg
Andrew Scheinberg
NMNadim Mahmud
Nadim Mahmud
TTTamar H. Taddei
Tamar H. Taddei
BDBassam Dahman
Bassam Dahman
The emergency use authorization (EUA) of 2 mRNA-based vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) heralded a rapid nationwide rollout to slow down the surge of coronavirus disease 2019 (COVID-19) infections. These vaccines have been highly effective in phase 3 clinical trials, offering recipients 94% to 95% protection from infection.1,2 However, stringent exclusion criteria excluded many individuals with chronic liver disease. For example, the phase 3 trial of the Pfizer BNT162b2 mRNA vaccine against COVID-19 excluded individuals with an anticipated need for immunosuppression, and those with active hepatitis B or C infection.1 Only 217 (0.6%) of participants had liver disease, with just 3 (<0.01%) with moderate-to-severe liver disease.3 A similarly low proportion of patients with liver disease were included in the Moderna mRNA-1273 trial with only 196 (0.6%) with liver disease.2,3

26 February 2021 in Hepatology
Verified
Journal Article
Closed access
PDF file
BJBinu V. John
Binu V. John
GAGabriella Aitcheson
Gabriella Aitcheson
KSKaley B. Schwartz
Kaley B. Schwartz
NKNidah Shabbir Khakoo
Nidah Shabbir Khakoo
BDBassam Dahman
Bassam Dahman
DKDavid E. Kaplan
David E. Kaplan